European Journal of Medicinal Chemistry p. 406 - 418 (2017)
Update date:2022-09-26
Topics:
Irie, Takayuki
Asami, Tokiko
Sawa, Ayako
Uno, Yuko
Hanada, Mitsuharu
Taniyama, Chika
Funakoshi, Yoko
Masai, Hisao
Sawa, Masaaki
Cdc7 is a serine-threonine kinase and plays a conserved and important role in DNA replication, and it has been recognized as a potential anticancer target. Herein, we report the design, synthesis and structure-activity relationship of novel furanone derivatives as Cdc7 kinase inhibitors. Compound 13 was identified as a strong inhibitor of Cdc7 with an IC50 value of 0.6?nM in the presence of 1?mM ATP and showed excellent kinase selectivity. In addition, it exhibited slow off-rate characteristics, which may offer advantages over known Cdc7 inhibitors in its potential to yield prolonged inhibitory effects in?vivo. Compound 13 potently inhibited Cdc7 activity in cancer cells, and effectively induced cell death.
View MoreShijiazhuang Haotian Chemical Co., Ltd.
Contact:86-311-85044374
Address:293 Donggang Road
Contact:+86-21-38122007
Address:2, Lane 1123, Kangqiao Road, Pudong New Area, Shanghai
Zhejiang Genebest Pharmaceutical Co.,Ltd.
Contact:0086-571-63532866
Address:No.1 Jinboshi Rd Lishan Town Fuyang City Zhejiang Province China
Chengdu D-Innovation Pharmaceutical Co., Ltd
Contact:86-28-85105536
Address:1001, B6, No.88 Keyuan South Road, Chengdu Hi-Tech Zone
Henan zhongda Biological Engineering Co., Ltd
Contact:86-28-18109029985
Address:shenzhou road,xuedian industrial estate,zhengzhou city,henan province CHN
Doi:10.1002/ejoc.201200323
(2012)Doi:10.1002/ejic.201200471
(2012)Doi:10.1021/jo00035a001
(1992)Doi:10.1055/s-0032-1316583
(2012)Doi:10.1134/S1070363212090241
(2012)Doi:10.1002/ejoc.201200679
(2012)